Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positivemetastatic breast cancer in patients with brain metastases: updated exploratory analysis of the HER2CLIMB randomized clinical trial (vol 9, pg 197, 2023)

被引：0
|
作者：
Mao, Yuanjie [1 ,2 ,4 ]
Zhong, Wenjun [3 ]
机构：
[1] Ohio Univ, Diabet Inst, Athens, OH USA
[2] Ohio Hlth Castrop Ctr, Diabet & Endocrinol Clin, Athens, OH USA
[3] Merck & Co Inc, Merck Res Labs, West Point, PA USA
[4] Ohio Univ, Diabet Inst, Pk Hall 149, Athens, OH 45701 USA
来源：
JAMA ONCOLOGY | 2023年 / 9卷 / 02期
关键词：
D O I：
10.1001/jamaoncol.2022.7864
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：284 / 284
页数：1
相关论文
共 50 条
  • [31] Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
    Krop, Ian E.
    Carey, Lisa A.
    Ramos, Jorge
    Chen, Yiyi
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+locally advanced or metastatic breast cancer with and without brain metastases
    Carey, L. A.
    Krop, I.
    Ramos, J.
    Feng, W.
    Hamilton, E.
    ANNALS OF ONCOLOGY, 2021, 32 : S510 - S511
  • [33] TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
    Ahluwalia, Manmeet
    Ozair, Ahmad
    Khosla, Atulya
    Bellur, Shreyas
    Kotecha, Rupesh
    McDermott, Michael
    Mehta, Minesh
    Sandoval-Leon, Ana
    Mahtani, Reshma
    Peereboom, David
    NEURO-ONCOLOGY, 2023, 25
  • [34] TUCATINIB, TRASTUZUMAB, AND CAPECITABINE WITH STEREOTACTIC RADIOSURGERY IN PATIENTS WITH BRAIN METASTASES FROM HER-2 POSITIVE BREAST CANCER (TUTOR): A MULTICENTER PHASE 1 CLINICAL TRIAL
    Ahluwalia, M. S.
    Khosla, A. A.
    Ozair, A.
    Kotecha, R. R.
    McDermott, M. W.
    Mehta, M. P.
    Sandoval-Leon, A. C.
    Mahtani, R.
    Peereboom, D. M.
    NEURO-ONCOLOGY, 2023, 25
  • [35] Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases
    Metzger Filho, O.
    Leone, J. P.
    Li, T.
    Tan-Wasielewski, Z.
    Trippa, L.
    Barry, W. T.
    Younger, J.
    Lawler, E.
    Walker, L.
    Freedman, R. A.
    Tolaney, S. M.
    Krop, I
    Winer, E. P.
    Lin, N. U.
    ANNALS OF ONCOLOGY, 2020, 31 (09) : 1231 - 1239
  • [36] SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations: HER2-mutated breast cancer cohort (ongoing clinical trial)
    Okines, Alicia
    Pohlmann, Paula R.
    Ramos, Jorge
    Walker, Luke
    Hamilton, Erika
    CANCER RESEARCH, 2022, 82 (04)
  • [37] HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
    Krop, Ian E.
    Ramos, Jorge
    Zhang, Chiyu
    Hamilton, Erika P.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] HER2CLIMB-04: Phase II trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally-advanced or metastatic breast cancer with and without brain metastases
    Hamilton, E.
    Ramos, J.
    Feng, W.
    Krop, I.
    ANNALS OF ONCOLOGY, 2021, 32 : S76 - S76
  • [39] Trastuzumab deruxtecan in patients with previously treated HER2-low advanced breast cancer and active brain metastases: the DEBBRAH trial
    Batista, M. Vaz
    Perez-Garcia, J. M.
    Cortez, P.
    Garrigos, L.
    Fernandez-Abad, M.
    Gion, M.
    Martinez-Bueno, A.
    Saavedra, C.
    Teruel, I.
    Fernandez-Ortega, A.
    Servitja, S.
    Ruiz-Borrego, M.
    de la Haba-Rodriguez, J.
    Martrat, G.
    Perez-Escuredo, J.
    Alcala-Lopez, D.
    Sampayo-Cordero, M.
    Braga, S.
    Cortes, J.
    Llombart-Cussac, A.
    ESMO OPEN, 2024, 9 (09)
  • [40] TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer
    Murthy, Rashmi K.
    O'Brien, Barbara J.
    Hess, Ken R.
    Navin, Nick
    Johnson, Jason
    Gule-Monroe, Maria
    Leone, Jose P.
    Specht, Jennifer
    Melisko, Michelle
    Morikawa, Aki
    Storniolo, Anna M.
    Brufsky, Adam
    Pohlmann, Paula R.
    Park, Deric M.
    Park, Ben H.
    Krop, Ian
    Lin, Nancy U.
    Wolff, Antonio
    Forerro-Torres, Andres
    Stringer-Reasor, Erica
    CANCER RESEARCH, 2020, 80 (04)
12345